Exclusive focus on innovative drug-development companies Global investment scope with a primary focus on Switzerland and Europe Team with deep expertise in investing, company building, and drug development First seven investments completed ST. PETER PORT, …
Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies LONDON, UK and BOSTON, USA, September 21, 2020 / B3C newswire / -- Immune Regulation Limited (“Immune Regulation …
International Live Events Starting off Again With euroPLX 73 Vienna VIENNA, Austria, September 15, 2020 / B3C newswire / -- Only 36 hours before the euroPLX 73 Marketplace for Pharma Business Opportunities started in Vienna, the Austrian Government …
GRONINGEN, The Netherlands, September 15, 2020 / B3C newswire / -- Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patients in its first-in-human …
Patent provides long term composition of matter protection LONDON, UK, September 08, 2020 / B3C newswire / -- Immune Regulation Ltd, a US and UK based clinical stage biotechnology company, today announced that it has received a notice of allowance from the …
POLLING, Germany, September 07, 2020 / B3C newswire / -- IcanoMAB, a privately-funded biotech company focusing on the pre-clinical and clinical development of novel precision canonical antibodies for the treatment of cancer, immune-system related diseases …
HEIDELBERG, Germany, September 07, 2020 / B3C newswire / -- Thanks to its novel real-cum-virtual Marketplace concept euroPLX 73 Vienna will be one of the first pharma partnering events, if not the first, to be held physically under pandemic conditions on …
MediSpin XL™ high-volume industrial electrospinning platform for both medical devices and new drug delivery applications WAALRE, The Netherlands, September 03, 2020 / B3C newswire / -- IME Medical Electrospinning, a global leader in electrospun medical …
LEIDEN, the Netherlands, September 03, 2020 / B3C newswire / -- Amarna Therapeutics, a privately held biotechnology company developing the next-generation SV40-based gene delivery vector platform named SVec™ that promises to transform gene-replacement and …
BASEL, Switzerland, September 01, 2020 / B3C newswire / -- BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of infectious disease candidates into first in human clinical trials and …
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell …
CARDIFF, UK, August 26, 2020 / B3C newswire / -- A new paper exploring the application of patient-derived organoids (PDOs) in the study of novel inhibitors of stem cell activity has recently been published in the journal PLOS ONE (Badder et al., 2020). The …
Study Focused on Advanced HER2-Expressing Cancer Patients With No More Effective Therapy Options NIJMEGEN, The Netherlands, August 25, 2020 / B3C newswire / -- Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) today announced that the first patients …
MetP Pharma`s Nascum®-VIREX is evaluated for its potential to prevent virus entry at the mucous membrane of the nose Nascum® attracts and blocks airborne particles such as in industrial dust and air pollution Airborne particles could spread the novel …
Collaboration accelerates a Q1 2021 comprehensive launch of MC2's WYNZORA® Cream to patients with plaque psoriasis in the US WYNZORA® Cream is the first drug based on PAD™ Technology - providing innovative solutions to unmet needs in chronic …
Secured additional funding for Covid-19 testing and back-up drug discovery LEIDEN, The Netherlands, August 20, 2020 / B3C newswire / -- Hercules Pharmaceuticals, a Dutch biopharmaceutical company focusing on developing small molecule inhibitors of the Aryl …
NIJMEGEN, The Netherlands, August 19, 2020 / B3C newswire / -- Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) is pleased to announce the appointment of Robbert Van Heekeren as chief financial officer. Mr. Van Heekeren will assume this role on …
Next Generation ADC Uses Proprietary Technologies Aimed at Enhancing Cancer Therapy Efficacy and Safety NIJMEGEN, The Netherlands, August 11, 2020 / B3C newswire / -- Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) today announced that the first …
NIJMEGEN, The Netherlands, August 11, 2020 / B3C newswire / -- Saillant Therapeutics, an innovative biotechnology start-up, developing promising small molecule-based therapies, today announced the swift advancement of an innovative groundbreaking generic …
Contract Development and Manufacturing Organization further expands its commitment to climate protection Focus on energy-efficient and environmentally friendly technology All European sites utilize green electricity Savings of more than 4,500 tons of …
